Kelley Larson

Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease

Microglial dysfunction is increasingly implicated in Alzheimer’s disease (AD) pathogenesis, with loss-of-function variants in the microglial receptor TREM2 as major risk factors for late-onset AD. We report VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages...

From rhetoric to reality: a critical whiteness studies scoping review of communicators' roles in advancing DEI in organizations

Purpose This scoping review examines how organizational communication and professional communicators are conceptualized within DEI-related scholarship and identifies recurring patterns in how communication sustains, obscures, constrains, resists, or transforms organizational Dive...